Maze Therapeutics is emerging as a key competitor to Vertex in developing APOL1 inhibitors for kidney disease, supported by strong Phase 2 trial results from its HORIZON study. The trial showed significant reductions in proteinuria, especially in non-diabetic and severe FSGS patients, paving the way for a pivotal trial in these groups. Vertex's progress with its AMPLITUDE trial provides regulatory and commercial momentum that benefits Maze's development path. Major catalysts expected in early 2027 include full HORIZON data release, interim AMPLITUDE results from Vertex, and regulatory feedback, with Maze's valuation reflecting recent market adjustments.
Maze Therapeutics is featured here with a snapshot of the health sector on Pluang as of Nov 13, 2026 17:21 WIB. Among 150 health-sector US stocks, 89 advanced while 52 declined today. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.35 with a 5.80% gain and a typical hold time of 39 days, Citius Pharmaceuticals Inc (CTXR) at USD 0.51 down 4.21%, and BioNano Genomics Inc (BNGO) at USD 1.00 down 3.85%.
The Philippines solar energy market is projected to grow from 5.43 GW in 2026 to 23.35 GW by 2032, with a CAGR of 27.46%. Growth is fueled by declining costs of solar panels and installation, government-backed renewable energy auctions, and increasin...
Equinor ASA shares will trade ex-dividend on the Oslo Stock Exchange starting November 13, 2026, for the second quarter of 2026. The declared dividend amount is $0.39 per share, payable in USD. This means investors buying shares from this date will n...
China Eastern Airlines signed 23 procurement agreements worth $540 million with 15 suppliers from eight countries at the 9th China International Import Expo in Shanghai. The deals cover aircraft engines, aviation materials, jet fuel, and in-flight ca...
Eramet announced a €500 million share capital increase through a rights issue, offering 6 new shares for every 5 existing shares at €14.49 each. The proceeds will be used to reduce the company's debt and strengthen its balance sheet as part of a prev...
Pasithea Therapeutics announced positive Phase 1/1b results for PAS-004, showing significant reductions in cutaneous neurofibromas (cNF) size by up to 71% with continued treatment and early activity in plexiform neurofibromas (PN). The drug demonstra...
